Pfizer CEO criticizes US drug price negotiation tactics.

Pfizer CEO Albert Bourla criticized the US government's plan to negotiate drug prices for its Medicare health program, calling it "negotiation with a gun to your head." He expects drugmakers to sue to halt the process, which is part of the Inflation Reduction Act and aims to save $25 billion through price negotiations by 2031. The pharmaceutical industry says the law will result in a loss of profits that will force drugmakers to pull back on developing groundbreaking new treatments. Bourla also expressed concerns about a recent ruling by a judge in Texas that suspended the approval of abortion pill mifepristone by the FDA.